Literature DB >> 31802987

Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis.

Paul J Pockros1.   

Abstract

Entities:  

Year:  2019        PMID： 31802987      PMCID： PMC6883731     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Management of Patients Who Have Achieved Sustained Virologic Response for Hepatitis C Virus Infection.

Authors:  Paul J Pockros
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

2.  Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

Authors:  Tarik Asselah; Stefan Bourgeois; Stephen Pianko; Stefan Zeuzem; Mark Sulkowski; Graham R Foster; Lingling Han; John McNally; Anu Osinusi; Diana M Brainard; G Mani Subramanian; Edward J Gane; Jordan J Feld; Alessandra Mangia
Journal:  Liver Int       Date:  2017-10-22       Impact factor: 5.828

3.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors:  Xavier Forns; Samuel S Lee; Joaquin Valdes; Sabela Lens; Reem Ghalib; Humberto Aguilar; Franco Felizarta; Tarek Hassanein; Holger Hinrichsen; Diego Rincon; Rosa Morillas; Stefan Zeuzem; Yves Horsmans; David R Nelson; Yao Yu; Preethi Krishnan; Chih-Wei Lin; Jens J Kort; Federico J Mensa
Journal:  Lancet Infect Dis       Date:  2017-08-14       Impact factor: 25.071

4.  Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C.

Authors:  Jason J Pan; Fei Bao; Emma Du; Chase Skillin; Catherine T Frenette; Jill Waalen; Lakshmi Alaparthi; Zachary D Goodman; Paul J Pockros
Journal:  Hepatol Commun       Date:  2018-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.